Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Queen RX vs Rixa Health

Queen RX
Graded #212

Higher grade

vs+5.5
Rixa Health
Graded #321

Lower grade

The verdict

Queen RX takes it — 66/100 to 60.5/100.

Queen RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Queen RX offers compounded GLP-1 treatment (semaglutide, tirzepatide, liraglutide) at $299/quarter (~$100/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +31
76
45
Dose & formulationQueen RX +6
57
51
Clinical oversightRixa Health +16
69
85
Labs & monitoringRixa Health +10
53
63
FulfillmentRixa Health +3
75
78
Contract termsQueen RX +20
61
41
Queen RX · left barRixa Health · right bar

The numbers

MetricQueen RXRixa Health
WeighScore66/10060.5/100
GradeCC
Scorecard rank#212#321
Semaglutide$100/mo (quarterly plan, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
Coverage45 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Queen RX

Graded #212 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV
Rixa Health

Graded #321 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard